HopeStage
Back to all studies
RecruitingNCT04628429

Autonomic function, migraine attacks, and medicines targeting CGRP

About this titleRead the official source — NCT04628429
Observational studyAges 18–64AustriaAnxiety
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 64 years.

Listed locations
ViennaSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: October 1, 2020
Recruitment status
Recruiting
Enrollment listed in the registry
120
Sponsor
Medical University of Vienna
Sponsor type
University
Study type
Observational
Intervention type
Drug
Locations
Austria
Age range
From 18 Years to 64 Years
Official registry ID
NCT04628429
Official title
Show the full official title

Autonomic Functions in Migraine Patients as a Function of Migraine Status and CGRP Inhibition

Recruitment & locations

Currently recruiting

Vienna

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Medical University of Vienna, a university.

Does this study involve medication?

Yes. The study involves medication, including Erenumab, Galcanezumab and Fremanezumab.

Who can participate?

Listed age limits: 18 years to 64 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies